膝关节假体周围感染微生物耐药模式:一项24年纵向研究
该研究纳入2000年至2023年间3家大型三级医院初次全膝关节置换术后的487例首次假体周围感染,分析病原菌与抗生素耐药谱的24年趋势。结果显示金黄色葡萄球菌最常见,耐药病例比例(19%至24%)在24年间保持稳定,假体在位不足1年是多种微生物感染和耐药感染的最重要危险因素。作者推荐早期假体周围感染经验性使用万古霉素联合革兰阴性菌覆盖,晚期血源性感染使用β-内酰胺类仍有效,脓毒症性感染无论时机均推荐万古霉素联合革兰阴性菌药物双联治疗。
要点
- 耐药病例比例在24年间保持稳定(19%至24%),主要致病微生物未变。
- 假体在位不足1年是多种微生物感染(风险约11倍)和耐药感染(风险约3倍)的最重要危险因素。
- 作者推荐早期假体周围感染经验性使用万古霉素联合革兰阴性菌覆盖,脓毒症性感染无论时机均推荐双联治疗。
核心结论
- 尽管已知医疗环境中耐药菌出现,膝关节假体周围感染的主要致病微生物在24年间保持不变,耐药病例无显著增加。
- 作者推荐早期假体周围感染经验性治疗选择万古霉素联合革兰阴性菌覆盖,β-内酰胺类如氟氯西林和第一代头孢菌素(如头孢唑林)对晚期血源性假体周围感染仍有效。
- 对于脓毒症性假体周围感染,无论感染时机,作者推荐万古霉素联合革兰阴性菌药物双联治疗。
研究设计与样本
- 本研究纳入2000年至2023年间在3家大型三级医院初次全膝关节置换术后识别的487例首次假体周围感染。
- 假体周围感染采用Tsukayama分类,该分类基于距初次全膝关节置换的时间及感染来源。
- 采用多变量逻辑回归分析多种微生物感染和耐药感染的危险因素。
主要发现
- 共识别487例假体周围感染病例,包含608份培养标本;患者平均年龄70±11岁,男性65%、女性35%。
- 种族数据均为自我报告:57%为新西兰欧洲人,14%为其他欧洲人,14%为太平洋岛民,10%为新西兰毛利人,6%为亚洲人。
- 假体周围感染最常见病原菌为金黄色葡萄球菌。
- 耐药病例比例(19%至24%)在24年期间保持一致。
- 假体在位不足1年是多种微生物感染(可能性约11倍)和耐药感染(可能性约3倍)的最重要危险因素。
关键数值与推荐
- 氟氯西林单药治疗覆盖45%的早期假体周围感染病例、57%的慢性假体周围感染病例和79%的晚期血源性病例。
- 万古霉素单药治疗在全部3类假体周围感染中覆盖≥78%,加用革兰阴性菌抗生素如庆大霉素或复方磺胺甲噁唑后覆盖增至>90%。
- 证据等级为预后III级。
临床怎么用
- 作者基于研究结果推荐早期假体周围感染经验性治疗选择万古霉素联合革兰阴性菌覆盖。
- 作者发现β-内酰胺类如氟氯西林和第一代头孢菌素(如头孢唑林)对晚期血源性假体周围感染仍有效。
- 作者推荐脓毒症性假体周围感染无论感染时机均采用万古霉素联合革兰阴性菌药物双联治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Understanding the causative microorganisms and initiating appropriate empirical antibiotics early are important in the management of knee periprosthetic joint infections (PJIs). The aim of this study was to identify trends in PJI microorganisms and antibiotic resistance profiles over 24 years to guide empirical antibiotic selection. METHODS: This study included 487 first-episode PJIs identified between 2000 and 2023 following primary total knee arthroplasty (TKA) at 3 large tertiary hospitals. PJIs were classified using the Tsukayama classification, which is based on the timing from the primary TKA and the source of infection. Multivariable logistic regression was used to analyze risk factors for polymicrobial and resistant infections. RESULTS: A total of 487 PJI cases with 608 culture specimens were identified. The mean patient age (and standard deviation) was 70 ± 11 years, with 65% male patients and 35% female patients. All ethnicity data were self-reported. Of the patients in this study, 57% were New Zealand European, 14% were other European, 14% were Pacific Islander, 10% were New Zealand Māori, and 6% were Asian. The most common pathogen for PJIs was Staphylococcus aureus . The proportion of resistant cases (19% to 24%) was consistent across the 24-year period. A prosthesis in situ for <1 year was found to be the most important risk factor for polymicrobial infections (11 times more likely) and resistant infections (3 times more likely). Flucloxacillin monotherapy covered 45% of early PJI cases, 57% of chronic PJI cases, and 79% of late hematogenous cases. In comparison, vancomycin monotherapy provided coverage of ≥78% across all 3 PJI classes, and adding a gram-negative antibiotic such as gentamicin or cotrimoxazole increased coverage to >90%. CONCLUSIONS: Despite the known emergence of resistant organisms in health-care settings, the primary causative microorganisms remained the same in knee PJIs, with no notable increase in resistant cases, over 24 years. Based on the findings of this study, vancomycin with gram-negative coverage is recommended as the empirical treatment of choice in early PJIs, and beta-lactams, such as flucloxacillin and a first-generation cephalosporin (e.g., cefazolin), were found to still be effective for late hematogenous PJIs. For septic PJI, dual therapy with vancomycin and a gram-negative agent is recommended, regardless of infection timing. LEVEL OF EVIDENCE: Prognostic Level III . See Instructions for Authors for a complete description of levels of evidence.
引用
- Guo R, Tay ML, Kim K, et al. Microbial Resistance Patterns in Periprosthetic Joint Infection of the Knee: A 24-Year Longitudinal Study. J Bone Joint Surg Am. 2026. PMID: 41490082. doi:10.2106/JBJS.25.00541
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。